DOI: 10.4455/eu.2021.006

Ernährungstherapie bei angeborenen Stoffwechselerkrankungen

Teil 3: Störungen des Fettstoffwechsels

Ulrike Och, Tobias Fischer, Thorsten Marquardt

Literatur

1. *Iqbal J, Hussain MM: Intestinal lipid absorption. Am J Physiol Endocrinol Metab 2009; 296(6): E1183–94.*
2. *Alves-Bezerra M, Cohen DE: Triglyceride Metabolism in the Liver. Compr Physiol 2017; 8(1): 1–8.*
3. *Ramasamy I: Recent advances in physiological lipoprotein metabolism. Clin Chem Lab Med 2014; 52(12): 1695–727.*
4. *Adeva-Andany MM, Carneiro-Freire N, Seco-Filgueira M, Fernández-Fernández C, Mouriño-Bayolo D: Mitochondrial β-oxidation of saturated fatty acids in humans. Mitochondrion 2019; 46: 73–90.*
5. *Kumari A: Beta Oxidation of Fatty Acids. In: Sweet Biochemistry: Elsevier 2018; 17–19.*
6. *Wanders RJ, Vreken P, den Boer ME, Wijburg FA, van Gennip AH, IJlst L: Disorders of mitochondrial fatty acyl-CoA beta-oxidation. J Inherit Metab Dis 1999; 22(4): 442–87.*
7. *Kim J-JP, Miura R: Acyl-CoA dehydrogenases and acyl-CoA oxidases. Structural basis for mechanistic similarities and differences. Eur J Biochem 2004; 271(3): 483–93.*
8. *Institute of Medicine (IOM): Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: National Academies Press 2005.*
9. *Deutsche Gesellschaft für Ernährung, Österreichische Gesellschaft für Ernährung, Schweizerische Gesellschaft für Ernährungsforschung, Schwerizerische Vereinigung für Ernährung (ed.): Referenzwerte für die Nährstoffzufuhr. 2nd ed. Bonn: Deutsche Gesellschaft für Ernährung 2019.*
10. *Shaw V (ed.): Clinical Paediatric Dietetics: Hoboken, New Jersey: Wiley 2020.*
11. *Gillingham MB, Scott B, Elliott D, Harding CO: Metabolic control during exercise with and without medium-chain triglycerides (MCT) in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency. Mol Genet Metab 2006; 89(1-2): 58–63.*
12. *Marten B, Pfeuffer M, Schrezenmeir J: Medium-chain triglycerides. International Dairy Journal 2006; 16(11): 1374–82.*
13. *Thevenet J, Marchi U de, Domingo JS, et al.: Medium-chain fatty acids inhibit mitochondrial metabolism in astrocytes promoting astrocyte-neuron lactate and ketone body shuttle systems. FASEB J 2016; 30(5): 1913–26.*
14. *Romano A, Koczwara JB, Gallelli CA, et al.: Fats for thoughts: An update on brain fatty acid metabolism. Int J Biochem Cell Biol 2017; 84: 40–5.*
15. *Vockley J, Burton B, Berry G, et al.: Effects of triheptanoin (UX007) in patients with long-chain fatty acid oxidation disorders: Results from an open-label, long-term extension study. J Inherit Metab Dis 2020.*
16. *Deutsches Institut für Medizinische Dokumentation und Information (DIMDI): Internationale statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme ICD-10-GM: 10. Revision, German Modification 2020.*
17. *Nennstiel U, Lüders A, Blankenstein O, et al.: Nationaler Screeningreport Deutschland 2017. Deutsche Gesellschaft für Neugeborenenscreening e. V. (DGNS) 2019: 1–47.*
18. *Merritt JL 2, Chang IJ: Medium-Chain Acyl-Coenzyme A Dehydrogenase Deficiency. In: Merritt JL 2, Chang IJ (eds.): GeneReviews® [Internet]: University of Washington, Seattle 2019.*
19. *Derks TGJ, van Spronsen FJ, Rake JP, van der Hilst CS, Span MM, Smit GPA: Safe and unsafe duration of fasting for children with MCAD deficiency. Eur J Pediatr 2007; 166(1): 5–11.*
20. *El-Gharbawy A, Vockley J: Inborn errors of metabolism with myopathy: defects of fatty acid oxidation and the carnitine shuttle system. Pediatr Clin North Am 2018; 65(2): 317–35.*
21. *Schaub J, Schulte F-J, Hoffmann GF, Lentze MJ, Spranger J, Zepp F: Pädiatrie: Grundlagen und Praxis. 4th ed. Berlin, Heidelberg: Springer 2014.*
22. *Zschocke J, Hoffmann GF: Vademecum metabolicum: diagnosis and treatment of inborn errors of metabolism. Forword by William L. Nyhan, San Diego, USA. 4th ed. s.l.: Schattauer GmbH Verlag für Medizin und Naturwissenschaften 2011.*
23. *Primassin S, Ter Veld F, Mayatepek E, Spiekerkoetter U: Carnitine supplementation induces acylcarnitine production in tissues of very long-chain acyl-CoA dehydrogenase-deficient mice, without replenishing low free carnitine. Pediatr Res 2008; 63(6): 632–7.*
24. *Gregersen N, Andresen BS, Corydon MJ, et al.: Mutation analysis in mitochondrial fatty acid oxidation defects: Exemplified by acyl-CoA dehydrogenase deficiencies, with special focus on genotype-phenotype relationship. Hum Mutat 2001; 18(3): 169–89.*
25. *Almannai M, Alfadhel M, El-Hattab AW: Carnitine Inborn Errors of Metabolism. Molecules 2019; 24(18).*
26. *Bennett MJ, Santani AB (eds.): GeneReviews® [Internet]: University of Washington, Seattle 2016.*
27. *Magoulas PL, El-Hattab AW: Systemic primary carnitine deficiency: an overview of clinical manifestations, diagnosis, and management. Orphanet J Rare Dis 2012; 7: 68.*
28. *Scaglia F, Wang Y, Singh RH, et al.: Defective urinary carnitine transport in heterozygotes for primary carnitine deficiency. Genet Med 1998; 1(1): 34–9.*
29. *Schulze A, Lindner M, Kohlmüller D, Olgemöller K, Mayatepek E, Hoffmann GF: Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications. Pediatrics 2003; 111(6 Pt 1): 1399–406.*
30. *Przyrembel H, Wendel U, Becker K, et al.: Glutaric aciduria type II: Report on a previously undescribed metabolic disorder. Clinica Chimica Acta 1976; 66(2): 227–39.*

31. *Och U, Fischer T, Marquardt T: Ernährungstherapie bei angeborenen Stoffwechselerkrankungen: Teil 2: Störungen des Aminosäurestoffwechsels. Ernährungs Umschau 2020; 67(10): M606–19.*
32. *al-Essa MA, Rashed MS, Bakheet SM, Patay ZJ, Ozand PT: Glutaric aciduria type II: observations in seven patients with neonatal- and late-onset disease. Journal of perinatology official journal of the California Perinatal Association 2000; 20(2): 120–8.*
33. *Angle B, Burton BK: Risk of sudden death and acute life-threatening events in patients with glutaric acidemia type II. Mol Genet Metab 2008; 93(1): 36–9.*
34. *Schiff M, Froissart R, Olsen RKJ, Acquaviva C, Vianey-Saban C: Electron transfer flavoprotein deficiency: functional and molecular aspects. Mol Genet Metab 2006; 88(2): 153–8.*
35. *Frerman FE, Goodman SI: Deficiency of electron transfer flavoprotein or electron transfer flavoprotein: ubiquinone oxidoreductase in glutaric acidemia type II fibroblasts. Proc Natl Acad Sci U S A 1985; 82(13): 4517–20.*
36. *Fischer T, Och U, Marquardt T: Long-term ketone body therapy of severe multiple acyl-CoA dehydrogenase deficiency: A case report. Nutrition 2019; 60: 122–8.*
37. *Goodman SI, Frerman FE: Glutaric acidaemia type II (multiple acyl-CoA dehydrogenation deficiency). J Inherit Metab Dis 1984; 7 Suppl 1: 33–7.*
38. *Cornelius N, Frerman FE, Corydon TJ, et al.: Molecular mechanisms of riboflavin responsiveness in patients with ETF-QO variations and multiple acyl-CoA dehydrogenation deficiency. Human molecular genetics 2012; 21(15): 3435–48.*
39. *Ghisla S, Thorpe C: Acyl-CoA dehydrogenases. A mechanistic overview. Eur J Biochem 2004; 271(3): 494–508.*
40. *Bonham JR, Tanner MS, Pollit RJ, et al.: Oral sodium-3-hydroxybutyrate, a novel adjunct to treatment for multiple acyl-CoA dehydrogenase deficiency. J Inherit Metab Dis 1999; 22(suppl): 101.*
41. *van Hove JLK, Grünewald S, Jaeken J, et al.: D,L-3-hydroxybutyrate treatment of multiple acyl-CoA dehydrogenase deficiency (MADD). The Lancet 2003; 361(9367): 1433–5.*
42. *Gautschi M, Weisstanner C, Slotboom J, Nava E, Zurcher T, Nuoffer J-M: Highly efficient ketone body treatment in multiple acyl-CoA dehydrogenase deficiency-related leukodystrophy. Pediatr Res 2015; 77(1-1): 91–8.*
43. *van Rijt WJ, Heiner-Fokkema MR, du Marchie Sarvaas, Gideon J, et al.: Favorable outcome after physiologic dose of sodium-D,L-3-hydroxybutyrate in severe MADD. Pediatrics 2014; 134(4): e1224–8.*
44. *van Rijt WJ, Jager EA, Allersma DP, et al.: Efficacy and safety of D,L-3-hydroxybutyrate (D,L-3-HB) treatment in multiple acyl-CoA dehydrogenase deficiency. Genet Med 2020; 22(5): 908–16.*
45. *Kumari A: Cholesterol Synthesis. In: Sweet Biochemistry: Elsevier 2018; 27–31.*
46. *Walzer S, Travers K, Rieder S, Erazo-Fischer E, Matusiewicz D: Homozygous familial hypercholesterolemia (HoFH) in Germany: an epidemiological survey. ClinicoEconomics and outcomes research CEOR 2013; 5: 189–92.*
47. *Talmud PJ, Shah S, Whittall R, et al.: Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: A case-control study. The Lancet 2013; 381(9874): 1293–301.*
48. *Klose G, Laufs U, März W, Windler E: Familial hypercholesterolemia: developments in diagnosis and treatment. Deutsches Arzteblatt international 2014; 111(31–32): 523–9.*
49. *Mach F, Baigent C, Catapano AL, et al.: 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European heart journal 2020; 41(1): 111–88.*
50. *Wolfram G, Bechthold A, Boeing H, et al.: Evidence-Based Guideline of the German Nutrition Society: Fat Intake and Prevention of Selected Nutrition-Related Diseases. Ann Nutr Metab 2015; 67(3): 141–204.*
51. *Bundesinstitut für Risikobewertung (BfR): Lebensmittel mit Pflanzensterol- und Pflanzenstanol-Zusatz: Bewertung einer neuen Studie aus den Niederlanden: Stellungnahme 006/2012 des BfR vom 1. Dezember 2011, ergänzt am 21. Januar 2013. 2011: 1–7.*
52. *Cabral CE, Klein MRST: Phytosterols in the treatment of hypercholesterolemia and prevention of cardiovascular diseases. Arq Bras Cardiol 2017; 109(5): 475–82.*
53. *Berger S, Raman G, Vishwanathan R, Jacques PF, Johnson EJ: Dietary cholesterol and cardiovascular disease: a systematic review and meta-analysis. Am J Clin Nutr 2015; 102(2): 276–94.*
54. *Carson JAS, Lichtenstein AH, Anderson CAM, et al.: Dietary Cholesterol and Cardiovascular Risk: A Science Advisory from the American Heart Association. Circulation 2020; 141(3): e39–53.*
55. *Vincent MJ, Allen B, Palacios OM, Haber LT, Maki KC: Meta-regression analysis of the effects of dietary cholesterol intake on LDL and HDL cholesterol. Am J Clin Nutr 2019; 109(1): 7–16.*
56. *Och U: Ernährungstherapie bei Hypercholesterinämie. Ernährungs Umschau 2018; 65(11): S73–6.*
57. *Porter FD, Herman GE: Malformation syndromes caused by disorders of cholesterol synthesis. J Lipid Res 2011; 52(1): 6–34.*
58. *Smith DW, Lemli L, Opitz JM: A newly recognized syndrome of multiple congenital anomalies. J Pediatr 1964; 64: 210–7.*
59. *Tint GS, Irons M, Elias ER, et al.: Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome. N Engl J Med 1994; 330(2): 107–13.*
60. *Movassaghi M, Bianconi S, Feinn R, Wassif CA, Porter FD: Vitamin D levels in Smith-Lemli-Opitz syndrome. Am J Med Genet A 2017; 173(10): 2577–83.*
61. *Porter FD: Smith-Lemli-Opitz syndrome: pathogenesis, diagnosis and management. Eur J Hum Genet 2008; 16(5): 535–41.*
62. *Sever N, Mann RK, Xu L, et al.: Endogenous B-ring oxysterols inhibit the Hedgehog component Smoothened in a manner distinct from cyclopamine or side-chain oxysterols. Proc Natl Acad Sci U S A 2016; 113(21).*
63. *Eroglu Y, Nguyen-Driver M, Steiner RD, et al.: Normal IQ is possible in Smith-Lemli-Opitz syndrome. Am J Med Genet A 2017; 173(8): 2097–100.*
64. *Kritchevsky D, Tepper SA: Solubility of cholesterol in various fats and oils. Proc Soc Exp Biol Med 1964; 116: 104–7.*
65. *Saad HY, Higuchi WI: Water solubility of cholesterol. J Pharm Sci 1965; 54(8): 1205–6.*
66. *Fischer T, Dütting S, Och U, Baumeister A, Marquardt T: Entwicklung einer Cholesterol-Emulsion zur ernährungstherapeutischen Anwendung bei Patienten mit Smith-Lemli-Opitz-Syndrom (SLO). In: Ernährung 2018 – Ernährung ist Therapie und Prävention. Stuttgart: Thieme 2018.*
67. *Fischer T, Dütting S, Och U, Baumeister A, Marquardt T: Sensorische und ernährungsphysiologische Adaption einer Cholesterol-Emulsion zum Einsatz bei Patienten mit Smith-Lemli-Opitz-Syndrom (SLO). In: Ernährung 2018 – Ernährung ist Therapie und Prävention. Stuttgart: Thieme 2018.*

DOI: 10.4455/eu.2021.006